Isotechnika Pharma Inc., of Edmonton, Alberta, received additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its Non-Immunosuppressive Cyclophilin Antagonist Molecules (NICAMs) program

Astellas Pharma US Inc., of Northbrook, Ill., part of Astellas Pharma Inc., entered a distribution agreement with Tecnofarma International Ltd., of Buenos Ares, Argentina, to distribute enzalutamide (Xtandi in the U.S.) in Latin America, excluding Brazil, upon regulatory approvals in the various countries

Horizon Pharma Inc., of Deerfield, Ill., said in an SEC filing that it provided written notice to Mallinckrodt LLC, the pharmaceuticals business of Dublin, Ireland-based Covidien LLC, of the termination of the companies' co-promotion agreement dated June 14, 2012, effective 30 days after the date of such notice

Hyperion Therapeutics Inc., of South San Francisco, said it completed the acquisition of Buphenyl (sodium phenylbutyrate) tablets and powder, from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International Inc., of Laval, Quebec, Buphenyl is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders (UCD...Maxygen Inc., of Redwood City, Calif., said its board approved the liquidation and dissolution of the company, subject to shareholder approval

Amgen Inc., of Thousand Oaks, Calif., and Astellas Pharma Inc., of Tokyo, signed a strategic alliance agreement to develop and commercialize five Amgen pipeline medicines in the areas of cardiovascular disease, bone disease and cancer in Japan...Cardiome Pharma Corp., of Vancouver, British Columbia, said its board adopted an advance notice policy regarding the nomination of directors, establishing a deadline and written process by which registered or beneficial holders of the company's common

AVEO Pharmaceuticals Inc., of Cambridge, Mass., said in an SEC filing that it was informed by partner Astellas Pharma Inc., of Tokyo, that Astellas no longer intends to submit a marketing authorization application to the European Medicines Agency for tivozanib for the treatment of patients with advanced renal cell carcinoma (RCC...Medivation Inc., of San Francisco, said partner Astellas Pharma Inc., of Tokyo, submitted an application for marketing approval in Japan for enzalutamide in prostate

Astellas Pharma Europe BV, of Meppel, The Netherlands, a subsidiary of Astellas Pharma Inc., reported the Dutch Medicines Evaluation Board granted marketing authorization for Vesomni (solifenacin + tamsulosin) in the Netherlands

The product is marketed by Genentech Inc., a member of the Basel, Switzerland-based Roche Group, and Astellas Pharma Inc., of Tokyo

Acceleron Pharma Inc., of Cambridge, Mass., said preclinical research conducted by Acceleron scientists on the ACE-536 program were presented at the 12th International Symposium on Myelodysplastic Syndromes in Berlin

Acceleron Pharma Inc., of Cambridge, Mass., said Shire plc, of Dublin, Ireland, concluded the firms' collaboration on ACE-031 and related molecules...In separate news, Hyperion said it exercised its option to acquire Buphenyl (sodium phenylbutyrate) tablets and powder, an FDA-approved therapy for the chronic management of the most prevalent UCDs, and Ammonul (sodium phenylacetate and sodium benzoate) injection, a hospital-based product used to treat UCD patients in hyperammonemic crisis, from

Addex Therapeutics SA, of Geneva, said regulatory authorities in the Netherlands gave approval to start in the first half of this year a Phase I study of ADX71441, a GABA-B receptor positive allosteric modulator, for Charcot-Marie-Tooth1A (CMT1A) neuropathy and other disease indications...for the Brisbane, Australia-based company's Diversity Scanning Array (DSA) and Versatile Assembly on Stable Templates (VAST) technologies in a deal worth up to $240 million in milestones, plus other payments

Novartis has worldwide rights to the drug, along with certain backup compounds in all indications, with Incyte retaining a co-development option to INC280 in the U.S...Due to third-party manufacturing issues, distribution of Janssen Products LP's Caelyx in Europe has been intermittently disrupted since 2011

Celgene Corp., of Summit, N.J., said the European Committee for Medicinal Products for Human Use adopted a positive opinion for Revlimid (lenalidomide) for the treatment of patients with transfusion-dependent anemia due to low or intermediate-1 risk myelodsyplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate...Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, said the European Committee

Addex Therapeutics, of Geneva, said regulatory authorities in the Netherlands gave approval to start in the first half of this year a Phase I study of ADX71441, a GABA-B receptor positive allosteric modulator, for Charcot-Marie-Tooth1A (CMT1A) neuropathy and other disease indications...Tranzyme Pharma Inc., of Research Triangle Park, N.C., and Ocera Therapeutics Inc., of San Diego, entered a definitive agreement under which Ocera will merge with a subsidiary of Tranzyme in an all-stock transaction

Armgo Pharma Inc., of Tarrytown, N.Y., and the Muscular Dystrophy Association (MDA) said $1 million was awarded for preclinical work in support of an investigational new drug application for AMR201, an oral, small-molecule Rycal drug that has the potential to treat Duchenne's muscular dystrophy

NovaDel Pharma Inc., of Bridgewater, N.J., signed a definitive agreement to sell its NovaMist technology and certain additional assets, including related patents and trademarks, to Australia's Suda Ltd

DFH Pharma Inc., of Gaithersburg, Md., said it entered a research and product development agreement with Hetero Group, a research-based pharmaceutical group headquartered in Hyderabad, India, to develop next-generation HIV maturation inhibitor drugs...Tris Pharma Inc., of Monmouth Junction, N.J., said the FDA approved its new drug application for Karbinal ER (carbinoxamine maleate) extended-release oral suspension, a sustained-release histamine receptor blocking agent indicated for the treatment of

A.P. Pharma Inc., of Redwood City, Calif., received a complete response letter from the FDA regarding the new drug application for APF530 for the prevention of chemotherapy-induced nausea and vomiting...In other news, SCT closed its previously announced private placement for gross proceeds of C$3.2 million (US$3.1 million

Astellas Pharma Inc., of Tokyo, and Nagasaki University signed a collaborative research agreement to discover new drugs for the treatment of neglected tropical diseases (NTDs) caused by dengue virus...In other news, The Nasdaq OMX Stockholm's listing committee approved the listing of NeuroVive's shares